Pharmaceutical Market Europe • July/August 2021 • 42-44
APPOINTMENTS
Barts Life Sciences
MARK CAULFIELD
Mark Caulfield has left Genomics England to take on the chief executive officer role at Barts Life Sciences – a research and innovation partnership between Queen Mary University of London and Barts Health NHS Trust. At Genomics England, Caulfield served as chief scientist and in 2013, he led the scientific oversight and delivery of the 100,000 Genomes Project. He was awarded a knighthood in 2019 following the project’s ‘unprecedented success’, Genomics England said in a statement. At Barts Life Sciences, Caulfield will be responsible for the overall leadership and delivery of the programme and will work alongside key stakeholders including the Department of Health and Social Care, Office for Life Sciences, London Borough of Tower Hamlets, NHS Property Services and Barts Charity.
AstraZeneca
SUSAN GALBRAITH
AstraZeneca has announced the appointment of Susan Galbraith as executive vice president, oncology research and development (R&D). Galbraith brings over 20 years of experience in drug discovery and development to the new position. Previously, she led early-stage oncology R&D at AZ, a role in which she oversaw the successful progression of seven programmes into phase 3 trials.
AstraZeneca
ARADHANA SARIN
AstraZeneca has also appointed Aradhana Sarin as its new chief financial officer and an executive director upon closing of the company’s acquisition of Alexion Pharmaceuticals, expected in the third quarter of 2021. Currently, Sarin serves as executive vice president and chief financial officer of Alexion. She has over 20 years of experience gained from operating and advisory roles.
EFPIA
HUBERTUS VON BAUMBACH
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has appointed Hubertus von Baumbach as president for the next two years. Von Baumbach is currently chairman of the board of managing directors at Boehringer Ingelheim and had been a member of Boehringer’s board of managing directors since 2009. He has also previously worked at Roche.
EFPIA
LARS FRUERGAARD JØRGENSEN AND OLIVIER LAUREAU
EFPIA has also confirmed Lars Fruergaard Jørgensen as its new first vice president and Olivier Laureau as second vice president. Fruergaard Jørgensen currently serves as the president and chief executive officer of Novo Nordisk, a role he has been in since January 2017, while Laureau serves as president of French pharma company Servier.
Moderna
PAUL BURTON
Moderna has announced the appointment of Paul Burton as chief medical officer. Burton joins Moderna after a 16-year stint at Johnson & Johnson. Since March 2020, he has served as chief global medical affairs officer of Janssen Pharmaceuticals, responsible for its global medical affairs strategy and execution. Previously, he served as Janssen’s vice president and head, CVM medical affairs.
CureVac
MALTE GREUNE
CureVac has appointed Malte Greune as its new chief operating officer. Greune joins from Sanofi-Aventis Deutschland GmbH, where he held a number of management roles. This included working as general manager and vice president, cartridges, devices & insulin technology group. Greune also previously held the position of head of diabetes, oncology and devices at Sanofi.
Merck & Co
MICHAEL KLOBUCHAR
Merck & Co – known as MSD outside the US and Canada – has appointed Michael Klobuchar as chief strategy officer. Prior to taking on this role, Klobuchar served as senior vice president, Merck Research Laboratories Finance and Global Project and Alliance Management. Before that, he was the company’s senior vice president, corporate strategy and financial planning.
Azafaros
STEFANO PORTOLANO
Dutch biotech company Azafaros has appointed Stefano Portolano as its new chief executive officer. Portolano has 25 years’ experience working in the biotech and pharma industries, with a focus on leadership roles in organisations that develop orphan speciality medicines. He joins Azafaros from Ultragenyx Pharmaceuticals, where he served as head of Europe since 2016.
Nordic Nanovector
MALENE BRONDBERG
Nordic Nanovector has appointed Malene Brondberg as its interim chief executive officer. Brondberg previously served as chief financial officer at the biopharma company prior to taking on the interim CEO role. She has over 20 years’ operational experience in the financial services sector, having initially joined Nordic Nanovector in 2018 as vice president of investor relations.
Orbit Discovery
NEIL BUTT
Neil Butt has been appointed as chief executive officer at Oxford-headquartered Orbit Discovery. Prior to joining Orbit, Butt most recently served as chief business officer of IONTAS. Before that, he was part of the management team that took Cambridge, UK biopharma company Abzena onto the London AIM market. He also served as head of business development at Antitope.
Vifor Pharma
ABBAS HUSSAIN
Vifor Pharma has appointed Abbas Hussain as chief executive officer. Between 2008 and 2017, Hussain held a number of leadership positions at GlaxoSmithKline, including as global president of pharmaceuticals and vaccines. Prior to that, he worked at Eli Lilly for 20 years, holding management positions in the US, Europe, Asia and Australia.
Cardior
RAHUL AGRAWAL
Cardior Pharmaceuticals has appointed Rahul Agrawal as chief medical officer. Agrawal brings over 20 years’ experience to the role, gained from global and senior medical positions focused on cardiac indications. He joins Cardior from AstraZeneca, where he most recently held the position of VP and global medicines leader, cardiovascular. He also previously worked at Bayer.
Alchemab Therapeutics
DOUGLAS TRECO
Douglas Treco has joined Alchemab Therapeutics as chief executive officer. Most recently, Treco was co-founder, president and chief executive officer of biotech company Ra Pharmaceuticals, which was acquired by UCB in 2020 for $2.5bn. Prior to that, he co-founded Transkaryotic Therapies, serving as senior vice president of research and development at the company.
Draupnir Bio
ANDREW HOTCHKISS
Danish biotech company Draupnir Bio has appointed Andrew Hotchkiss as chief executive officer. Hotchkiss brings over 30 years’ global experience in the pharma and biotech industries to the role. He joins from Dermira, a dermatology-focused biopharma company wholly owned by Eli Lilly, where he served as chief executive officer and chief commercial officer.
Stellate Therapeutics
DAVID IMMKE
David Immke has joined French biotech company Stellate Therapeutics as chief scientific officer. Prior to joining Stellate, Immke spent 17 years at Amgen as head of neuroscience research, vice president of R&D transformation and as the medical scientific lead for migraine treatment Aimovig. Immke will be responsible for overseeing the company’s corporate research and technology strategies and also R&D.
Stellate Therapeutics
JONATHAN WEISS
Stellate Therapeutics has also appointed Jonathan Weiss as director of business development. Weiss joins Stellate from Kadmon Pharmaceuticals, where he worked as a principal scientist responsible for the team’s biologic drug development project in the autoimmune space and bringing the drug – Belumosudil – from preclinical in vitro and animal studies through to clinical trials.
Horizon Therapeutics
PETRA MOLAN
Petra Molan has joined Horizon Therapeutics as group VP, general manager of Europe, Middle East and Africa (EMEA). Molan joins Horizon from Arvelle Therapeutics, where she served as SVP, head of commercial operations. Prior to Arvelle, she worked as SVP, head of global rare haematology franchise at Takeda and SVP, head of global medicine franchise at Shire.
VarmX
JAN ÖHRSTRÖM
VarmX has appointed Jan Öhrström as chief executive officer, after serving as chairman at the Dutch biotech company since November 2018. Öhrström brings extensive experience across biotech and pharma to VarmX, having held management positions in large and mid-sized pharma companies in both the EU and US. He also previously served as chief executive officer of ProFibrix.
iosBio
PATRICIA LONDONO-HAYES
UK-based biotech company iosBio has appointed Patricia Londono-Hayes as chief development officer. Londono-Hayes has more than 20 years’ experience in the pharma and biotech sectors and joins the company from Sanofi Pasteur, where she most recently served as head of external R&D initiatives and scientific affairs, Europe. Before joining Sanofi Pasteur, she worked at vaccine company Acambis.
Tiziana Life Sciences
KEVIN SHUTZ
Tiziana Life Sciences has appointed Kevin Shutz as vice president of regulatory affairs. In this role, Shutz will lead regulatory interactions related to the company’s clinical studies in Europe, the US and Asia. He brings over 19 years’ pharma industry experience to the role, including 14 years of regulatory affairs experience and a focus on disease indications with high unmet medical needs.
McCann Health
MATT SILVER
McCann Health New York has announced the promotion of Matt Silver to the new role of president. Silver first joined McCann Health in 2017, initially taking on the role of executive vice president and managing director in New York. Prior to joining McCann Health, Silver served as senior vice president of strategy and engagement at Razorfish Health.
Ashfield MedComms
AGUSTIN RAMIREZ
Ashfield Health has appointed Agustin Ramirez to the role of global strategy director for Ashfield MedComms. Prior to joining Ashfield, Ramirez worked at McCann Health for over 11 years, most recently serving as strategy director & SVP global clients, EMEA. In his new role at Ashfield, he will focus on working with key stakeholders across the business.
Resonant Group
ANNA KORVING
Anna Korving has joined Resonant Group as a non-executive director and advisor to the board. Industry veteran Korving previously took a group of agencies from start up through to acquisition by Publicis Health, to create the integrate service offerings Publicis Life Brands Resolute – now known as Langland. She also created Women in Health Agency Management in 2015.
Resonant Group
STEPHEN MARCHANT
Resonant Group has appointed Stephen Marchant to the new role of chief development officer. Previously Marchant was group client strategy officer at Omnicom’s Healthcare Consultancy Group. He also worked at Chameleon Communications International for over 16 years, where he most recently served as president of group strategy and growth.
COUCH Health
MARK DUMAN
Patient engagement and health comms agency COUCH Health has appointed Mark Duman as chief strategy officer. Duman has over 30 years’ experience working in the healthcare/pharmaceutical industries, having worked with clients including AstraZeneca, the Department of Health, Johnson & Johnson, NHS England, Novartis, Roche Diagnostics and more.
Evoke KYNE
CAROLYN COYLE
Evoke KYNE has announced the promotion of Carolyn Coyle to executive vice president. Coyle will continue to serve as a relationship manager for one of Evoke’s largest client engagements. Coyle has over 15 years’ experience in the healthcare communications industry, with expertise in strategic brand and franchise communications and disease awareness programming.
Ashfield Advisory
MARY-KATE MCGARRY
Ashfield Advisory has appointed Mary-Kate McGarry to the new role of vice president of strategy. McGarry has 15 years’ experience in management consulting, primarily gained at Ernst & Young and Accenture. She will be responsible for driving all aspects of the company’s strategy and will work closely with the M&A team, and will also oversee the organisation’s change programme.
Hanover Health
ALEKSANDRA LUGOVIC
Hanover Health has appointed Aleksandra Lugovi´c as an associate director in its international policy and market access team. Lugovi´c joins from GOPA Com. Brussels, where she ran global campaigns for the European Commission across the EU, US, Africa and Asia. Prior to that, she headed the regional representation of South Serbia to the EU for six years.
Ashfield Advisory
EMER JAMESON
Ashfield Advisory has appointed Emer Jameson as vice president of HR. Prior to joining the company, Jameson had a varied career working in international HR and commercial roles, including time spent working at Saongroup in China and as global chief people officer covering the Pacific area, Caribbean and Central America at Digicel.
Ashfield Engage
SERAP BECKER
Ashfield Engage has announced the appointment of Serap Becker as its new head of patient solutions in the DACH region (Austria, Germany, and Switzerland). Prior to joining Ashfield Engage, Becker served as director of direct to patient services at Marken. She has 20 years’ experience in clinical trials and a customer-driven focus.
Virgo Health
AMANDA MOULSON
Amanda Moulson has joined Virgo Health as an executive director. For more than 20 years, Moulson has worked in healthcare communications, gaining pan-European and global experience as a strategic adviser in the healthcare and well-being sectors. Moulson will be responsible for leading two of Virgo’s key accounts and will play an ‘important’ role in the agency’s leadership team.
Virgo Health
GREGOR FYFE
Gregor Fyfe has been appointed as senior scientific director at healthcare communications agency Virgo Health. Fyfe joins Virgo Health from Ashfield Health, where he was director of editorial operations. Fyfe brings a wealth of experience to the medical education team and will be responsible for building and integrating Virgo’s scientific services team.